Equities analysts expect that Cognex Co. (NASDAQ:CGNX) will report sales of $178.87 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Cognex’s earnings. The lowest sales estimate is $176.30 million and the highest is $182.17 million. Cognex posted sales of $129.32 million during the same quarter last year, which suggests a positive year over year growth rate of 38.3%. The company is scheduled to report its next earnings report on Thursday, February 15th.

On average, analysts expect that Cognex will report full-year sales of $178.87 million for the current year, with estimates ranging from $743.90 million to $749.76 million. For the next year, analysts anticipate that the business will report sales of $845.21 million per share, with estimates ranging from $800.82 million to $897.56 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Cognex.

Cognex (NASDAQ:CGNX) last released its earnings results on Monday, October 30th. The scientific and technical instruments company reported $0.57 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.05. The company had revenue of $259.74 million during the quarter, compared to the consensus estimate of $255.95 million. Cognex had a net margin of 34.77% and a return on equity of 23.31%. The company’s revenue was up 75.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.31 EPS.

Several equities research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Cognex from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Canaccord Genuity boosted their target price on shares of Cognex from $47.50 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, October 31st. Robert W. Baird lifted their price target on shares of Cognex from $50.00 to $62.00 and gave the company a “neutral” rating in a report on Tuesday, October 31st. ValuEngine lowered shares of Cognex from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Zacks Investment Research raised shares of Cognex from a “hold” rating to a “buy” rating and set a $69.00 price target for the company in a report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $60.17.

In other Cognex news, Director Patrick Alias sold 5,000 shares of the business’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $143.54, for a total transaction of $717,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodor Krantz sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $134.05, for a total transaction of $2,010,750.00. Following the transaction, the director now directly owns 26,250 shares of the company’s stock, valued at $3,518,812.50. The disclosure for this sale can be found here. Insiders have sold a total of 143,750 shares of company stock valued at $18,540,975 over the last three months. 5.60% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. AHL Partners LLP lifted its stake in shares of Cognex by 0.8% in the 2nd quarter. AHL Partners LLP now owns 2,842 shares of the scientific and technical instruments company’s stock worth $241,000 after acquiring an additional 23 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Cognex by 0.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,645 shares of the scientific and technical instruments company’s stock worth $1,074,000 after acquiring an additional 75 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Cognex by 7.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,295 shares of the scientific and technical instruments company’s stock worth $280,000 after acquiring an additional 237 shares during the period. Stifel Financial Corp raised its holdings in shares of Cognex by 2.4% in the 2nd quarter. Stifel Financial Corp now owns 15,563 shares of the scientific and technical instruments company’s stock worth $1,316,000 after purchasing an additional 364 shares in the last quarter. Finally, LS Investment Advisors LLC raised its holdings in shares of Cognex by 5.1% in the 3rd quarter. LS Investment Advisors LLC now owns 8,996 shares of the scientific and technical instruments company’s stock worth $992,000 after purchasing an additional 439 shares in the last quarter. 42.10% of the stock is owned by institutional investors.

Cognex (CGNX) traded up $1.40 on Monday, hitting $67.78. 1,805,276 shares of the stock traded hands, compared to its average volume of 1,646,000. The company has a market cap of $11,740.00, a P/E ratio of 49.84 and a beta of 1.50. Cognex has a one year low of $31.51 and a one year high of $72.99.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/08/178-87-million-in-sales-expected-for-cognex-co-cgnx-this-quarter-2.html.

About Cognex

Cognex Corporation (Cognex) is a provider of machine vision products that capture and analyze visual information in order to automate tasks, primarily in manufacturing processes, where vision is required. The Company operates through the machine vision technology segment. The Company’s machine vision products are used to automate the manufacture and tracking of discrete items, such as mobile phones, aspirin bottles and automobile tires, by locating, identifying, inspecting and measuring them during the manufacturing or distribution process.

Get a free copy of the Zacks research report on Cognex (CGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.